Related references
Note: Only part of the references are listed.Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time
Emma C. Hulshof et al.
EUROPEAN JOURNAL OF CANCER (2020)
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype
David Paez et al.
BRITISH JOURNAL OF CANCER (2019)
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Femke M. de Man et al.
CLINICAL PHARMACOKINETICS (2018)
Pharmacogenetic Information in Clinical Guidelines: The European Perspective
Jesse J. Swen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification
Michele Boisdron-Celle et al.
SEMINARS IN ONCOLOGY (2017)
Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy
Xing-Han Liu et al.
JOURNAL OF CANCER (2017)
Cost Evaluation of Irinotecan-Related Toxicities Associated With the UGT1A1*28 Patient Genotype
R. Roncato et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance
Bettina Butzke et al.
ACTA ONCOLOGICA (2016)
Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study
D. J. Crona et al.
PHARMACOGENOMICS JOURNAL (2016)
Dose-Finding and Pharmacokinetic Study to Optimize the Dosing of Irinotecan According to the UGT1A1 Genotype of Patients With Cancer
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians
X. Liu et al.
PHARMACOGENOMICS JOURNAL (2014)
UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine
Matthew P. Goetz et al.
INVESTIGATIONAL NEW DRUGS (2013)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
A genotype-directed phase I-IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer
E. Marcuello et al.
BRITISH JOURNAL OF CANCER (2011)
Clinical Implications of UGT1A1*28 Genotype Testing in Colorectal Cancer Patients
Katerina Shulman et al.
CANCER (2011)
Genotype-directed, dose-finding study of irinotecan in cancer patients with UGT1A1☆28 and/or UGT1A1☆6 polymorphisms
Taroh Satoh et al.
CANCER SCIENCE (2011)
Dose-Dependent Association between UGT1A1*28 Genotype and Irinotecan-Induced Neutropenia: Low Doses Also Increase Risk
Zhe-Yi Hu et al.
CLINICAL CANCER RESEARCH (2010)
Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: A meta-analysis
Zhe-Yi Hu et al.
EUROPEAN JOURNAL OF CANCER (2010)
Genotype-Driven Phase I Study of Irinotecan Administered in Combination With Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results From North American Gastrointestinal Intergroup Trial N9741
Howard L. McLeod et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost Effectiveness of Pharmacogenetic Testing for Uridine Diphosphate Glucuronosyltransferase 1A1 Before Irinotecan Administration for Metastatic Colorectal Cancer
Heather Taffet Gold et al.
CANCER (2009)
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
Crystal S. Denlinger et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Irinogenetics: How Many Stars Are There in the Sky?
Ron H. J. Mathijssen et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial
Michael S. Braun et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Federico Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
D. M. Kweekel et al.
BRITISH JOURNAL OF CANCER (2008)
Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer
Marko Obradovic et al.
PHARMACOGENOMICS (2008)
The role of UGT1A1*28 polymorphism in the pharmacodynarnics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer
Giuseppe Toffoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy
C Massacesi et al.
CANCER (2006)
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan
F Innocenti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer
E Marcuello et al.
BRITISH JOURNAL OF CANCER (2004)
Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity:: A molecular and clinical study of 75 patients
E Rouits et al.
CLINICAL CANCER RESEARCH (2004)
Irinotecan pharmacokinetics-pharmacodynamics: the clinical relevance of prolonged exposure to SN-38
RHJ Mathijssen et al.
BRITISH JOURNAL OF CANCER (2002)
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose-escalating study of irinotecan and cisplatin
MJA de Jonge et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
